Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis

T. Enomoto, Yukihiro Noda, T. Nabeshima

研究成果: Review article査読

55 被引用数 (Scopus)


In humans, phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, PCP-treated animals have been utilized as an animal model of schizophrenia. PCP-treated animals exhibit hyperlocomotion as an index of positive symptoms, and a social behavioral deficit in a social interaction test and enhanced immobility in a forced swimming test as indices of negative symptoms. They also show a sensorimotor gating deficit and cognitive dysfunctions in several learning and memory tests. Some of these behavioral changes endure after withdrawal from repeated PCP treatment. Furthermore, repeated PCP treatment induces some neurochemical and neuronanatomical changes. Recently, genetic approaches based on "the glutamate hypothesis of schizophrenia" have been used to develop animal models of schizophrenia. NMDA receptor subunit ζ1 knockdown, ε1 knockout (KO) and ζ1 point mutant mice exhibiting a hypofunction of NMDA receptors show hyperlocomotion, social behavioral deficit, sensorimotor gating deficit or cognitive dysfunction. Forebrain-specific calcineurin KO, neuregulin 1 heterozygous KO and lysophosphatidic acid 1 receptor KO mice can also serve as animal models of schizophrenia. These findings suggest that PCP and genetic animal models would be useful for evaluating novel therapeutic candidates and for confirming pathological mechanisms of schizophrenia.

ジャーナルMethods and Findings in Experimental and Clinical Pharmacology
出版ステータスPublished - 05-2007

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬理学(医学)


「Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。